Core Insights - Allogene Therapeutics reported a narrower loss of 19 cents per share for Q3 2025, compared to an expected loss of 23 cents and a loss of 32 cents per share in the same period last year [1][6] - The company's shares have decreased by 51% year-to-date, while the industry has seen an 11% growth [1] Financial Performance - Research and development (R&D) expenses were $31 million, a decrease of 30% from the previous year [3][6] - General and administrative (G&A) expenses fell by 16% year-over-year to approximately $14 million [3][6] - As of September 30, 2025, Allogene had $277 million in cash and cash equivalents, down from $303 million as of June 30, 2025 [3][6] 2025 Guidance - The company reiterated its guidance for 2025, expecting total operating expenses to be around $230 million, which includes nearly $45 million in non-cash stock-based compensation [4] - Cash burn for 2025 is anticipated to be around $150 million, with the current cash position expected to fund operations into the second half of 2027 [4][6] Pipeline Updates - Allogene is focused on the pivotal phase II ALPHA3 study for its lead drug cema-cel, targeting newly diagnosed large B-cell lymphoma patients [7] - The company has initiated the phase I RESOLUTION basket study for ALLO-329, exploring its potential in various autoimmune diseases, with data expected in the first half of 2026 [8] - Allogene is also developing ALLO-316, currently in the phase I TRAVERSE study for advanced renal cell carcinoma, and is seeking partnership opportunities for its development [9] Market Position - Allogene currently holds a Zacks Rank of 4 (Sell) [10]

Core Viewpoint - Allogene Therapeutics reported a first-quarter 2025 loss of 28 cents per share, which aligns with the Zacks Consensus Estimate, showing an improvement from a loss of 38 cents per share in the same period last year [1] Financial Performance - The company did not report any sales during the quarter, as it lacks a marketed product, compared to collaboration revenues of $0.02 million in the year-ago period [1] - Research and development (R&D) expenses were $50.2 million, down 4% year over year, while general and administrative (G&A) expenses decreased by 13% to $15.0 million [5] - As of March 31, 2025, Allogene had $335.5 million in cash, cash equivalents, and investments, down from $373.1 million as of December 31, 2024 [5] 2025 Guidance - Allogene revised its 2025 guidance, expecting operating expenses to be around $230 million, including nearly $45 million in non-cash stock-based compensation, an improvement from the previous forecast of $250 million [6] - Cash burn for 2025 is now expected to be around $150 million, reduced from the previous guidance of $170 million, allowing the company to extend its cash runway into the second half of 2027 [7] Pipeline Updates - The pivotal phase II ALPHA3 study is evaluating lead drug cema-cel for treating newly diagnosed large B cell lymphoma patients, with the timeline for analysis pushed back to the first half of 2026 [9] - Allogene plans to initiate the phase I RESOLUTION basket study with ALLO-329 for autoimmune diseases in mid-2025, with the first data readout now expected in the first half of 2026 [10] - Updated data from the phase I TRAVERSE study evaluating ALLO-316 in advanced renal cell carcinoma will be presented at the 2025 ASCO Annual Meeting on June 1 [11] Stock Performance - Year to date, Allogene's shares have declined by 47%, contrasting with a 6% decline in the industry [2]